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 Transforaminal Lumbar Interbody Fusion is commonly performed with the use of off-
label recombinant human bone morphogenetic protein-2. Despite its widespread use, bone 
morphogenetic protein-2 has been linked with postoperative complications in observational 
studies. However, no experimental study has supported this association nor has the relative risk 
as compared to iliac crest bone graft been quantified. In this study, we will compare the 
incidence proportion of radiculopathy, heterotopic ossification, and vertebral endplate 
osteolysis following Transforaminal Lumbar Interbody Fusion in patients who receive 
recombinant human bone morphogenetic protein-2 versus patients who receive iliac crest 
bone graft. Specifically, we will carry out a single-blinded, randomized controlled trial to assess 
incidence through six months of follow-up. The insights gathered will guide patient and surgeon 

















A. Degenerative Disc Disease of the Lumbar Spine  
 
 i. Description and Diagnosis  
 
 Degenerative disc disease (DDD) affects millions of adults today and is a common cause 
of life-altering disability.1,2 As described by Battié, there is variability in how DDD is defined 
across the literature; however, we define the diagnosis as the combination of radiographic 
evidence of degenerative changes in the spine and the presence of corresponding symptoms as 
the term is used in the surgical community.3,4 DDD can occur at a single level or multiple levels 
of the spine, most commonly occurs in the cervical and lumbar regions, and seldom occurs in the 
thoracic spine. This work will focus on DDD of only the lumbar spine. 
 The most common degenerative changes supporting a diagnosis of DDD are spondylosis, 
spondylolisthesis, spondylolysis, spinal stenosis, and disc herniation.5 All are diagnosed 
radiographically. Patients may have more than one of these changes at a single vertebral level or 
distinct changes at different levels. One pathology may provoke another; for example, the 
fracturing of the pars interarticularis that defines spondylolysis can result in the anterior slippage 
of one vertebrae relative to another characterized as spondylolisthesis.6 Spondylosis or 
degenerative arthritis describes a broad array of degenerative changes that can appear as a loss of 
disc height, facet joint arthropathy, osteophyte formation, or hypertrophy of the ligamentum 
flavum.7,8 Next, disc herniation occurs when part of the nucleus pulposus seeps through a tear in 
the annulus. Finally, if degenerative changes narrow the vertebral canal or neural foramina, 
spinal stenosis results. 
 Symptoms secondary to these anatomic changes manifest on a case-by-case basis and 
according to the underlying pathology. The most common symptoms include low back pain, leg 
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pain, and neurogenic claudication.9 Weakness, tingling, numbness, and sensory loss may all be 
manifestations of neurogenic claudication. Symptoms may be intermittent or consistent, bilateral 
or unilateral, or exacerbated by positional changes and physical loads.10 Also, patients may have 
symptoms and degenerative changes that are unrelated, so clinicians must be discerning in 
making the diagnosis.11 A careful history, physical exam, and judicious use of imaging and other 
diagnostics such as discography or nerve conduction studies are used to aid clinical reasoning.12 
Other potentially serious causes of low back pain that must be ruled out include infection, 
neoplasm, fracture, cauda equina syndrome, referred pain, and rheumatologic disease.13 
Ultimately the patient’s symptoms must be clinically judged to be related to the their 
radiographic changes to be treated as DDD. 
 ii. Prevalence  
 DDD is commonly implicated as a cause of chronic low back pain, a leading cause of 
disability, healthcare utilization, and medical costs.9,14,15 The 2010 Global Burden of Disease 
study ranked low back pain as the number one cause of years lost to disability with 83 million 
disability-adjusted life years lost.2 Some studies suggest that chronic low back pain persisting 
beyond three months affects 15-45% of the U.S. adult population during their lifetimes and 8% 
of all U.S. adults at any given time are currently experiencing chronic low back pain of more 
than six months duration.16-19 Back pain was the principal reason for 13 million office visits in 
2010.20 Mild to moderate cases of DDD frequently remain undiagnosed if the patient’s 
symptoms are managed successfully in which case imaging and surgical consideration are not 
recommended.21,22  
While the majority of cases of DDD are managed conservatively, severe DDD qualifying 
for surgical candidacy is a massive problem on its own. Ravindra et al. found that in 2015, 266 
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million individuals worldwide or 3.63% of the population had both degenerative spine disease 
and low back pain described to be neurosurgically relevant by the authors.1 Higher income 
countries were associated a higher density of cases; in the U.S. and Canada, the prevalence was 
5% or 16 million affected persons. This is likely an underestimate of the true number since the 
study did not include other common symptoms of DDD such as neurogenic claudication. 
 Many individuals with severe DDD do go on to receive surgery. DDD is the most 
common indication for both decompressive and fusion surgery, and these surgeries are 
performed widely.23 Using a nationally representative database, Martin et al. calculated that 
approximately 174,000 elective lumbar fusions were performed in the U.S. for a diagnosis of 
spondylolisthesis, spondylolysis, spondylosis, or disc herniation in 2015.24 In recent years, the 
number of lumbar fusions performed per year has more than doubled every decade, increasing by 
220% between 1990 and 2001 and by 118% from 1998 to 2014.25-27 Decompressive surgeries 
remain common but appear to be decreasing, probably in favor of fusion.28 In 2011, around 
525,000 laminectomies and discectomies were performed inpatient in the U.S. (although this 
number includes cervical cases), and many more were performed in an outpatient setting.29-31 
 iii. Causes and Risk Factors  
 There is evidence that normal aging of the spine causes degenerative changes.32,33 Aging 
is associated with cellular-level differences including decreased amounts of collagen and other 
proteoglycans even in healthy adults who never experience symptoms.34,35 These changes, along 
with minor injuries from daily stressors, cause a gradual weakening of the annulus fibrosus, a 
loss of disk height, and alteration of load distribution on the vertebral facets. This can lead to 
pathologic adaptations: facet joints may shift, osteophytes may form to limit excess motion, and 
annular tears may leak nucleus pulposus.36 In most adults, these adaptations are asymptomatic 
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and, if identified, incidental.10 However, in other cases they may cause compression of nerve 
roots (either directly or indirectly from increased intrathecal pressure secondary to spinal canal 
narrowing), release of inflammatory signals by injured structures, and grinding of arthritic facets. 
 In addition to old age, other risk factors for developing lumbar DDD are numerous. 
Those identified at this time include female gender, genetic factors, lower socioeconomic status, 
smoking, obesity, diabetes, arthritis, vibration (such as that imposed by riding in a motor 
vehicle), trauma, physically strenuous work, and sedentary lifestyle.37-42 Preventing DDD 
involves minimizing modifiable risk factors. A healthy lifestyle including engaging in regular 
activity, consuming a balanced diet, maintaining a healthy weight, and choosing not to smoke is 
recommended to reduce one’s risk.43 Utilizing proper body mechanics when lifting objects is 
also important.44 
 iv. Treatment   
 The primary treatment for all patients with DDD is conservative. Nonsurgical treatment 
options shown to be helpful for varying durations include physical therapy, exercise-based 
interventions, CBT, mind-body techniques, and passive therapies like chiropractic care and 
massage.12 NSAIDs and acetaminophen are first-line pharmacologic treatments, and opioid use 
is not recommended in almost all cases.45 All patients should trial conservative management for 
a minimum of 12 weeks with 6 to 12 months considered a more appropriate duration in anything 
but the most severe cases.22 Patients experiencing symptoms lasting beyond 12 weeks rarely 
achieve a complete resolution of symptoms and should be counseled that the goals of treatment 
are to reduce disability and pain.46 
 Patients with symptoms refractory to conservative management may consider surgical 
treatment. Laminectomy, foraminotomy, discectomy, nuceloplasty, facetectomy, arthroplasty, 
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spinal cord stimulator placement, and spinal fusion are all important options in the surgeon’s 
arsenal for the treatment of DDD.47 Spinal fusion techniques include posteriorlateral fusion 
(PLF) and lumbar interbody fusion (LIF). PLF fuses adjacent vertebrae by means of pedicle 
screws and overlying osteoconductive material which grows to connect the transverse 
processes.48 The LIF technique involves removing the intervertebral disc and then inserting a 
device filled with osteoconductive material in the empty space. If the fusion is successful, new 
bone will form between the vertebral bodies, joining them firmly together. The intraoperative 
goals of LIF are to secure instabilities, restore lordosis, correct deformity, and decompress neural 
elements all toward the ultimate goal of reducing the patient’s symptoms of DDD.49 
 LIF is performed from a variety of different approaches that are named according to the 
relation of the operative site to the transverse process. The approaches relevant to this work 
include the include Anterior (ALIF), Oblique (OLIF), Transforaminal (TLIF), and Posterior 
(PLIF) techniques. ALIF and OLIF involve a supine or laterally positioned patient and generally 
pose a risk of damage to intra-abdominal and/or retroperitoneal structures.50 Patients are 
positioned prone for PLIF and TLIF and approached by a midline or bilateral paramedian 
incision; damaged or at-risk structures include the paraspinal muscles, spinal nerve roots, dura, 
and ligamenum flavum.51 PLIF and TLIF can each be performed alone but are usually combined 
with the PLF technique for added stability. Each of these approaches has distinct advantages and 
disadvantages that are considered in the context of the patient and surgeon. In general, no 
approach is considered clearly better than another. Additionally, it is worth noting LIF is 
sometimes performed by means of minimally-invasive variants; however, some studies suggest 
advantages and disadvantages specific to these techniques and due this potential risk of 
confounding, this work will only consider open surgeries.52  
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 Apart from cases of progressive and severe neurologic deficits, surgical treatment is 
elective and the decision to operate should be made on a case-by-case basis by the patient and 
surgeon. Evidence exists that surgical treatment can reduce symptoms and improve functioning 
in the right patient.53-62 The American Pain Society and American Association of Neurological 
Surgeons (AANS) recommend fusion as an option for patients with DDD.63 Specifically, AANS 
recommends lumbar fusion for intractable low back pain due to spondylosis, disc herniation 
associated with spinal instability, or other severe degenerative changes and also for stenosis due 
to spondylolisthesis, deformity, or instability.22,64-66 The guidelines do not recommend one 
lumbar fusion technique over another; this is left to the surgeon’s judgement.  
B. Transforaminal Lumbar Interbody Fusion  
 
 i. Description 
 TLIF is a common method to achieve lumbar fusion. One study representing 25 million 
patients over a six year period ending in 2009 found that posterior interbody approaches (PLIF 
and TLIF) comprised 55% of all fusions performed and were significantly more common in the 
elderly.27 Another report found that the annual number of posterior interbody fusions increased 
by 23% between 2011 and 2014.67 Posterior approaches are popular because they are well known 
and comfortable to most spine surgeons and allow optimal visualization of nerve roots and direct 
neural decompression.68 TLIF is essentially a newer, revised version of PLIF that approaches the 
intervertebral space from one side rather than two, limiting paraspinal injury, neural retraction, 
and facet disruption.69 Therefore, TLIF is the preferred posterior technique for many surgeons.  
 TLIF is suitable for fusions between L1-S1. As mentioned, the patient is positioned prone 
and a midline or bilateral paramedian incision is made.51,70 After the incision, the paraspinal 
muscles are dissected to reveal the lateral margins of the vertebral facets. Then, a unilateral 
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laminectomy and facetectomy are performed to access the spinal canal. The surgeon now 
prepares to remove the intervertebral disc. Following discectomy, the vertebral endplates are 
prepared for the incoming implant which may be a cage, spacer, or structural graft. Osteogenic 
material is placed within the implant and also distributed around it to cover the vertebral 
endplates. Usually, bilateral pedicle screw fixation with posterolateral fusion is also performed to 
provide further stability and a posterior tension band. Radiographic confirmation of proper 
hardware placement and biomechanical restoration is obtained before closure.  
 The gold standard of osteogenic material used in fusion is autogenous iliac crest bone 
graft (ICBG).71 It is harvested as struts capable of bearing weight or as morselized bone from the 
patient minutes before fusion. Other options include local autogenous graft, which is repurposed 
bone fragments from the surgical site, and allograft. Local autograft and allograft are limited by 
availability, and allograft also carries a theoretical risk of provoking an immune reaction.72 
Finally, bone graft extenders and substitutes may augment these materials or replace them 
entirely; common ones include demineralized bone matrix, ceramics, and bone morphogenetic 
proteins (BMPs).  
 ii. Outcomes  
 Research supports TLIF as a safe and effective treatment. An early study of 55 patients 
with DDD found significant reductions in pain and disability as measured by the Visual Analog 
Scale (VAS) and Oswestry Disability Index (ODI), respectively, through an average of 46 
months of follow-up.73 Operation time, complication rate, and estimated blood loss were 
comparable to other fusion techniques, and fusion rate was 89% with use of ICBG. Other studies 
have supported these findings: one meta-analysis of 19 studies involving TLIF confirmed 
significant reductions in back VAS, leg VAS, and ODI scores and another meta-analysis found a 
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fusion rate of 89.6% in 371 patients undergoing TLIF.74,75 The present-day fusion rate may be 
even higher; a recent meta-analysis of 21 articles including 432 patients who underwent a single-
level TLIF at L5/S1 found a fusion rate of 99.3% using autograft. However, most of these studies 
did not use computed tomography which is more sensitive for non-union than radiograph.76  
C. Recombinant Human Bone Morphogenetic Protein-2  
 i. Description and Advantages 
 Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a popular substitute for 
ICBG in LIF, including TLIF, due to its association with several advantages. Perhaps the biggest 
advantage of using rhBMP-2 is the elimination of adverse events associated with harvesting 
ICBG. These events are significant and numerous; pain, hematoma formation, paresthesias, or 
infection occur at least 50% of cases.77 One systematic review found that 60% of patients 
experience donor site pain, and another study concluded that between 18-31% of patients still 
experienced pain at 24 months postoperatively.78,79 Between 2% and 5% require re-operation due 
to wound complications. Other less common but important complications include iliac wing 
fracture and nerve and vascular injuries.  
 Next, rhBMP-2 likely increases fusion rates. One meta-analysis of ten RCTs involving 
ALIF or PLIF found that rhBMP-2 significantly decreased the risk of fusion failure at 24 months 
(RR=0.31) and decreased the rate of re-operation (RR=0.52) in comparison to ICBG.75 Another 
study independently re-analyzed the initial industry-sponsored data used to apply for FDA 
approval of rhBMP-2 and found a 12% increased fusion rate versus ICBG in ALIF.80  
 Finally, there are many patient populations in which rhBMP-2 may be particularly useful. 
The North American Spine Society recommends considering rhBMP-2 for use in patients at high 
risk for non-union or patients with poor-quality autogenous bone.81 In practice, these high risk 
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patients may comprise many if not most patients; those considered at high risk include patients 
with very common conditions such as hypertension, diabetes, osteoporosis, and tobacco use. 
RhBMP-2 is also useful in revision cases, multi-level fusions (to reduce extensive ICBG 
harvesting) and patients with rheumatoid arthritis or prior radiation therapy.82  
 ii. Mechanism of Action  
 
 Bone morphogenetic protein-2 (BMP-2) is a dimeric protein molecule endogenously 
produced by mesenchymal stem cells and osteoblasts in the bone matrix.83,84 It is a powerful 
osteoinductive agent. It functions as a ligand, interacting with receptors on cell membranes and 
activating a signaling cascade which eventually regulates gene transcription.85 This cascade 
ultimately promotes the differentiation of mesenchymal cells into osteoblasts, allowing 
osteogenesis and bone formation. These processes occur throughout life.  
 RhBMP-2 is molecularly identical to BMP-2 but artificially produced from a hamster 
ovary cell line. The desired clinical effect of rhBMP-2, enhancement of solid bone fusion, is 
achieved through the same mechanism as endogenous BMP-2.86 Introducing exogenous rhBMP-
2 to the body exponentially increases the natural physiologic concentration, powerfully 
stimulating osteoblast maturation and bone formation.  
 iii. Indications    
 
 RhBMP-2 has been approved for use by the FDA since 2002. The patent was given to 
Medtronic (Memphis, TN) which markets the product as Infuse™ Bone Graft.87 Initial studies 
reported a benefit of an increased radiographic fusion rate with rhBMP-2 versus the ICBG 
control in single level ALIF between L4-S1.77 Currently, rhBMP-2 is FDA approved for use in 
spinal fusion at a single level between L2-S1. Use is only permitted in combination with one of 
the manufacturer’s intended interbody devices and the absorbable collagen sponge (ACS) carrier 
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in which rhBMP-2 is dissolved. Approved surgical approaches include OLIF and open, 
retroperitoneal, or laparoscopic ALIF depending on the interbody device. The OLIF approach 
carries additional limitations on the level at which it may be used, either L5-S1 or L2-L5, again 
depending on the device. RhBMP-2 is not approved for use in TLIF.  
 iv. Off-Label Use in TLIF 
 Although it remains off-label, rhBMP-2 use in TLIF is very common. Between 40-50% 
of TLIFs in the U.S. were performed with rhBMP-2 in 2011.88 In fact, the most common use of 
Infuse™, a multi-billion dollar industry in the U.S. alone, is for off-label TLIF or PLIF, 
comprising 30% of all use of the product in 2009.89 Interestingly, the evidence so far has not 
shown increased fusion rates with use in TLIF. One recent retrospective cohort study found a 
92.7% fusion rate with rhBMP-2, nearly identical to the control group of ICBG or local 
autograft.90 Another meta-analysis involving 17 studies including TLIF found rhBMP-2 
minimally increased fusion with a rate of 95.0% (CI 92.8%-96.5%) in the intervention versus 
93.0% (CI 78.1-98.0%) in the autograft control.91  Despite the lack of a clear fusion benefit, 
these studies do show that rhBMP-2 is effective and therefore can still retain the advantage of 
avoiding ICBG morbidity.  
D. Selected Potential Complications of rhBMP-2 use in TLIF  
 
 i. Introduction  
 
 Since its approval, rhBMP-2 has often been the subject of controversy regarding its 
safety. In 2008, the FDA released a public health notification warning about potential life-
threatening airway compromise due to rhBMP-2 use in the cervical spine, specifically from local 
inflammation or fluid collections caused by the product.92 In its on-label use, rhBMP-2 was 
recognized to pose a greater risk of retrograde ejaculation than was previously described.93 Many 
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suspected bias and lost confidence in the safety conclusions of the initial trials after it was made 
known that the authors of the studies received lucrative payouts from Medtronic, while others 
emphasized that that the initial FDA statement noted some evidence for a variety of 
complications that was largely ignored.86 Finally, another rhBMP-2 product of a higher dose was 
submitted to the FDA for approval by Medtronic but rejected due to concerns regarding an 
association with malignancy.   
 Safety concerns for use of rhBMP-2 in TLIF have also been raised. Since its widespread 
adoption, reports of radiculopathy, heterotopic ossification (HO), and endplate osteolysis 
attributed to rhBMP-2 use in TLIF have surfaced.94,95 These complications are of concern to 
patients and surgeons as they can cause recurrent or new onset back pain or leg pain, hardware 
and fusion failure, or serious spinal cord compression and cases may require re-operation.96 
There is anatomic rationale for why these complications may be more frequent in a TLIF 
approach than as reported in the initial trials using ALIF. In ALIF, the posterior annulus and 
posterior longitudinal ligament are left intact and shield spinal nerves and posterior structures 
from rhBMP-2, but in TLIF these structures are dissected. Yet, the risk of radiculopathy, HO, 
and endplate osteolysis in TLIF have not yet been quantified by any experimental study. Many 
have described the need for high-quality studies to promote safe rhBMP-2 use.97  
 ii. Radiculopathy 
 Radiculopathy following TLIF manifests as persistent or recurrent pain, numbness, 
weakness, or tingling in a dermatomal distribution and originates from compressive or non-
compressive causes.12 Compression from heterotopic bone growth, fluid collection including 
hematoma and seroma, scar tissue, or recurrent stenosis can displace and irritate nerve roots, 
causing symptoms. Non-compressive causes of radiculopathy chiefly include radiculitis and 
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iatrogenic injury. Radiculitis refers to worsening pain in a dermatomal distribution ipsilateral to 
the surgical side that is secondary to an inflammatory process.98 A diagnosis of radiculopathy is 
made after incomplete decompression, infection, traction injury, implant migration, and chronic 
neuropathy have been ruled out. MRI and/or CT are used to identify or rule out structural 
pathologies. 
 Laboratory in-vivo studies have successfully demonstrated a plausible mechanism for 
rhBMP-2 induced radiculitis. Two separate studies found that BMP-2 receptors are present on 
both central and peripheral nervous system cells, and rhBMP-2 is able to trigger these receptors 
directly.99,100 Other studies have found that the rhBMP-2 mechanism is associated with a 
significant inflammatory response involving cytokine release a million times greater than that 
triggered by physiologic BMP-2 concentrations.101 One experiment performing PLF using 
rhBMP-2 in a rat model found increased macrophage infiltration in and around the dorsal root 
ganglia on histology versus saline control.102 The rats also displayed increased mechanical 
allodynia between three and ten days postoperatively. Finally, a case study of a man with 
radiculopathy following TLIF with rhBMP-2 found a fibrovascular stroma with extensive 
lymphocytes and eosinophils typical of an inflammatory healing response on histologic 
examination of the affected nerve root.101  
 iii. Heterotopic Ossification 
 HO can occur if rhBMP-2 leaks from the interbody space into the spinal canal or neural 
foramina and forms undesirable new bone outside of the target area.103 As rhBMP-2 is capable of 
inducing bone formation on its own, the mechanism is assumed to be identical to that of rhBMP-
2 in the intervertebral space. One published case study reported ectopic chondrocyte metaplasia 
among a fibrovascular stroma and immature bone on histology of a HO lesion, consistent with 
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the known mechanism of BMP-2.104 Ectopic ossification is sometimes used to describe the same 
process but to a more severe extent; however, this work will not make this distinction. A 
diagnosis of HO is made by imaging, either CT or MRI, and the patient may present with pain or 
radicular complaints.  
 iv. Osteolysis 
 Endplate osteolysis, or bony resorption, results from excessive osteoclastic activity. 
Osteolysis is part of a normal remodeling process in progression to fusion, but excessive 
resorption can destabilize the implant and cause subsidence, loosening, or migration.105 Endplate 
osteolysis is also associated with increased postoperative pain. Perhaps paradoxically, rhBMP-2 
can induce unnecessary bone breakdown. In vitro and in vivo studies have shown that rhBMP-2 
affects cells of the osteoclastic lineage by interfering with the balance of bone breakdown and 
bone formation, acting directly on the osteoclasts and their precursors, or both.106 Studies have 
noted the osteolytic phase induced by rhBMP-2 appears to be transient and osteolytic activity 
stops after 4-12 weeks; however, it may be consistent with decreased mineral densities seen on 
postoperative CT months later.83,107 Diagnosis is made with radiograph or CT.  
 Finally, it should be noted that radiculopathy, heterotopic ossification, and osteolysis are 
often related; for example, heterotopic bone growth usually becomes symptomatic by impinging 
on surrounding nerves. Or, excessive osteolysis allowing cage migration may induce heterotopic 
ossification in the spinal canal or neural foramina. 
1.2 Statement of the Problem  
 
 Lumbar DDD is highly prevalent in the general population and its symptoms are one of 
the most common causes of disability in U.S. adults.1,9 Many studies have shown that patients 
are choosing lumbar fusion with increasing frequency every year, and TLIF is a popular choice 
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due to its association with several advantages and high fusion rates.27 About half of TLIF 
surgeries are performed with off-label rhBMP-2 which allows patients to bypass the morbidity 
associated with ICBG and may aid fusion especially in populations at risk for nonunion.89 
Despite this widespread use, a number of recent observational studies describe increased rates of 
radiculopathy, heterotopic ossification, and endplate osteolysis in TLIF procedures performed in 
conjunction with off-label rhBMP-2, raising concerns about its safety.97 However, no 
experimental study has described the incidence of these complications and the true risk remains 
unclear. As hundreds of thousands of patients are likely to undergo TLIF in the coming decades, 
accurate safety information is needed to reliably guide patients and surgeons as they weigh the 
risks and benefits of different osteogenic materials.  
1.3 Goals and Objectives 
 
 The goal of this study is to evaluate the safety of rhBMP-2 use in TLIF using a high-
quality, experimental design. Therefore, we propose a single-blinded, randomized controlled trial 
to quantify the incidence of radiculopathy, heterotopic ossification, and endplate osteolysis in 
patients who undergo TLIF with off-label rhBMP-2 in comparison to TLIF performed with gold 
standard ICBG. Our study will involve multiple surgical centers in the Unites States and enroll 
hundreds of patients. Participants will be randomized to receive either rhBMP-2 or ICBG and we 
will measure our primary outcomes through six months of follow up. Radiculopathy will be 
determined by the same medical team that performed the surgery as a clinical diagnosis of 
exclusion, and the presence of heterotopic ossification or osteolysis will be assessed by 
independent orthopedic surgeons who will review each patient’s CT imaging. We will also 
quantify a variety of intraoperative, perioperative, and secondary postoperative complications. 
Overall, this study will provide a thorough assessment of the relative risk of developing 
postoperative complications from electing to use rhBMP-2 over ICBG in TLIF.  
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1.4 Hypothesis  
 
 A. Among adults undergoing TLIF for DDD, patients who receive rhBMP-2 during 
surgery will not have a statistically significant difference in postoperative incidence of 
radiculopathy than patients receiving ICBG. 
 B. Among adults undergoing TLIF for DDD, patients who receive rhBMP-2 during 
surgery will not have a statistically significant difference in postoperative incidence of 
heterotopic ossification than patients receiving ICBG.  
 C. Among adults undergoing TLIF for DDD, patients who receive rhBMP-2 during 
surgery will not have a statistically significant increase in postoperative incidence of endplate 
osteolysis than patients receiving ICBG.  
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1 Introduction   
 
 We conducted a thorough review of the literature between December 2020-May 2021 
using PubMed, Scopus, Embase, Web of Science, and Ovid. Only articles written in English 
were considered. We reviewed the titles, abstracts, and methods sections of each identified study 
to determine relevancy. Key terms employed to find articles relating to the study population and 
intervention included: lumbar fusion, posterior lumbar fusion, interbody fusion, transforaminal 
lumbar interbody fusion, TLIF, BMP, rhBMP-2, rhBMP, bone morphogenetic protein, 
recombinant human bone morphogenetic protein, Infuse™. The following terms were used to 
identify outcomes: radiculopathy, radiculitis, leg pain, back pain, radicular, heterotopic 
ossification, ectopic ossification, ectopic bone, osteolysis, osteolytic, complication, outcome.  
Confounding variables were identified by adding these key words: dose, demographic, narcotic, 
opioid, osteoporosis, cage, device, PEEK, titanium. Finally, additional terms to find studies with 
relevant methodology include: iliac crest bone graft, versus, randomized controlled trial, 
methods, design.  
2.2 Review of Empiric Studies  
A. Radiculopathy  
 Around 2009, reports of radiculopathy in TLIF began to surface. That year, Rihn et al. 
published a retrospective study of 48 patients undergoing single-level TLIF with rhBMP-2, 
reporting that 8 patients (16.7%) sustained new onset postoperative radiculopathy.1 Patients were 
U.S. adults between the ages of 18 and 80 with a degenerative indication for surgery. All patients 
developing radiculopathy were imaged with CT. In our judgement, it appears two of these eight 
cases appear less likely to be related to rhBMP-2; one case was attributed by the authors to a 
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malpositioned screw and the other to a deep infection. However, in both cases radicular 
symptoms did not improve with appropriate treatment for these likely causes so an rhBMP-2 
effect cannot be entirely excluded. The remaining six cases are more easily associated with 
rhBMP-2 use: a structural cause was not identified in five cases and the final case was deemed 
secondary to ectopic bone growth. 
 Later the same year, Rihn et al. expanded on this report by publishing another study that 
included a larger sample size and an ICBG control group.2 The study retrospectively examined 
119 adult patients undergoing single-level TLIF for a degenerative indication. A similar 
incidence was found: 12 of 86 (14%) patients in the rhBMP-2 group developed radiculopathy. 
However, it appears that this study’s sample only expanded the sample described in the previous 
study, as for both studies the authors state their population was the same single institution during 
the same time frame. Again, two cases of radiculopathy were attributed to a malpositioned screw 
and a deep infection, respectively, but the rest could be consistent with rhBMP-2 use. In the 
ICBG control, 1 of 33 patients (3%) developed radiculopathy and no identifiable cause was 
found. This clinical trend lacked statistical significance (p=0.08).  
 Many recent publications have supported these findings with incidence rates near the low 
teens. Lubelski et al. reported new onset radiculopathy in 12.5% of 216 patients undergoing 
either TLIF or PLIF.3 All of the cases were deemed idiopathic; none were attributed to 
compression. The advantages of this study include a fairly large sample size and use of multiple 
surgeons, increasing generalizability. However, the descriptive design did not include a control 
group, limiting comparisons with other populations including ICBG. Also, in contrast to Rihn et 
al, degenerative indications were not the only indication for surgery in this sample and included 
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postlaminectomy syndrome, pseudoarthrosis, and osteomyelitis. The percentage of patients with 
these indications is unclear, but the authors note that they comprise a minority.  
 Next, Villavicencio and Burneikiene retrospectively described new onset radiculitis in 23 
of 203 patients (11.3%) who underwent TLIF with rhBMP-2 at either at one or two levels.4 This 
number may underestimate the incidence of radiculopathy as we define it; we include both 
structural and inflammatory causes, but the authors of this study excluded all structural causes in 
their definition. Each subject experiencing radicular symptoms received an MRI to rule out 
structural causes, but it is not stated how many patients, if any, were found to have structural 
findings. However, we note that in each of the previously reviewed studies, the large majority of 
cases were consistent with an inflammatory etiology rather than a compressive one and this 
work’s incidence rate is consistent with these prior studies in a sizable sample.  
 Finally, a retrospective cohort study in 2018 authored by Khan et al. found a significantly 
greater risk of developing radiculopathy in rhBMP-2 treated patients undergoing TLIF than the 
autograft control (OR 4.53, CI 1.42-14.5).5 The incidence of radiculopathy was 9 of 83 (10.8%) 
in the rhBMP-2 group and 2 of 104 (1.9%) in the autograft control. All patients were U.S. adults 
undergoing TLIF for a degenerative condition with two years of radiographic and clinical 
follow-up. Each case of radiculopathy was attributed to an inflammatory cause, but the authors 
note that CT studies were not routinely attained to assess for structural causes. Overall, this study 
compares favorably to the incidence rates of the above studies in a sizable sample and also 
concludes a statistically significant higher incidence than that seen in autograft. Taken together, 
these studies suggest an increased risk of radiculopathy in TLIF performed with rhBMP-2 
compared to autograft, with an incidence between 10.8-14.0%.  
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 It must be noted that some studies have not found similar rates of radiculopathy with 
rhBMP-2 use in TLIF. In 2011, Owens et al. found an overall incidence of radiculopathy in 13 of 
204 patients (6.4%) undergoing TLIF with rhBMP-2.6 Two of these cases appear unrelated to 
rhBMP-2 use; one case involved a malpositioned screw and the other an epidural hematoma. 
Five cases (2.5%) were associated with local inflammatory changes likely due to rhBMP-2 use. 
The remaining six cases (3%) were idiopathic; the authors argued these rates were consistent 
with the known incidence in TLIF independent of rhBMP-2 use. Indeed, as the retrospective 
study did not include a control group, the likely cause of these cases remains unclear. 
Nevertheless, even if all six cases were assumed to be due to rhBMP-2, the incidence rate of 
cases probably attributable to rhBMP-2 (5.4%) is still lower than previous studies.  
 Another study by Sebastian et al. using a prospective cohort model found 0% incidence 
of radiculopathy in U.S. adults undergoing TLIF with rhBMP-2 for degenerative diagnoses.7 
However, sample size was small, including only 29 patients, and short-lived cases of 
radiculopathy may have been missed as the first clinical follow-up was six weeks following 
discharge. This study falls short of strong contradictory evidence.  
 The published incidence of radiculopathy in TLIF performed with autograft appears to be 
between 1.9-5.0%. As described above, this is supported by Rihn et al. and Khan et al., reporting 
an incidence of 1 of 33 (3%) and 2 of 104 (1.9%), respectively, in their control groups.2,5 In 
addition, Hackenberg et al. report an incidence of 1 of 52 (1.9%) in their prospective study of 
TLIF safety and efficacy using autograft.8 Similarly, Potter et al. retrospectively describe an 
incidence of new onset radiculopathy in 7 of 140 (5%) intervertebral levels treated by TLIF with 
autograft.9 Together, these studies suggest that new onset radiculopathy in TLIF with autograft is 
consistently present in low rates. 
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B. Heterotopic Ossification  
 
 The formation of heterotopic bone when using rhBMP-2 appears to be introduced by 
Haid et al. in a prospective, randomized trial published in 2004.10 Although the study intended to 
include hundreds, only 67 patients enrolled before the trial was suspended as 24 of 32 patients 
(75%) developed HO on imaging. In contrast, 4 of 31 patients (13%) randomized to the ICBG 
control developed such findings. Technical differences may be one factor contributing to these 
high rates; the authors do not describe an effort to place the rhBMP-2-soaked ACS as anteriorly 
as possible as became common in later studies. The rhBMP-2/ACS complex was placed centrally 
and no use of surrounding grafts was described. Perhaps surprisingly, the authors concluded their 
results were encouraging. They stated that no clinical correlation to HO was found through two 
years of follow-up, arguing that the investigational and control groups sustained similar rates of 
increased postoperative leg pain. Regardless, such a high rate of HO, even if asymptomatic, 
concerned some other surgeons.  
 In the following years, case reports surfaced that detailed clinically significant cases of 
HO, refuting the conclusion that HO was solely a radiographic phenomenon. Wong et al. 
reported five patients undergoing either PLIF or TLIF with rhBMP-2 who subsequently 
developed symptomatic HO.11 Three of these patients underwent revision to remove the growth 
and their symptoms subsided. Others criticized the techniques used for these patients noting that 
in each, the drain was placed deep to the fascia and the opening was irrigated after rhBMP-2 
implantation. Later, Rosen, Kiester, and Lee reported 38 cases of symptomatic HO following 
TLIF with rhBMP-2.12 The author described consistent “pseudo-pedicle” formations across the 
cases that were only sufficiently identified with CT.  
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 Next, two small, prospective studies offered contributions. Joseph and Rampersaud 
studied 33 patients, 22 of whom received rhBMP-2 and the remaining 10 autograft alone.13 
Patients underwent TLIF (70%) or PLIF and CT was obtained for all cases. Radiographic HO 
occurred at 5 of 24 levels (21%) in the rhBMP-2 group and 1 of 12 levels (8%) of the autograft at 
a mean eight months of follow up. The authors concluded this was a clinically insignificant 
difference, but admitted that the small sample size prevents strong conclusions.  
 Sebastian et al. found a statistically significant difference between the rhBMP-2 sample 
and ICBG control.7 The study included 77 single-level TLIF patients, with 29 in the 
interventional group and 48 in the control. HO was observed in 7 of 29 patients (20.7%) using 
rhBMP-2 and 1 of 48 (2.1%) using ICBG (p=0.013). All patients had radiographic follow-up 
through least six months, but mean follow-up is not specified. Radiographs and CT were used 
according to surgeon preference, but the proportion of diagnostic choice is not specified.  
 Another large study was conducted by Niu et al. in 2020. Using a retrospective cohort 
model that included 927 TLIF patients and routine use of CT during follow up, they reported a 
statistically significant increase in HO in the rhBMP-2 treated group than the autograft control 
after controlling for demographics and comorbidities (OR 9.56, p=0.026).14 The incidence was 
13.5% in the intervention and 1.6% in the control. This study’s large cohort, superior imaging, 
and comparison with a control group provide strong support for their conclusions.  
 While these studies suggest an association between rhBMP-2 use and HO, several other 
studies have published very low or nonexistent rates of HO. First, Mummaneni et al. 
retrospectively described 40 patients undergoing TLIF: 21 received rhBMP-2 and 19 received 
autograft.15 None of the intervention group were found to have symptomatic foraminal bone 
formation at a mean nine months of follow up. Notably, this study was performed at the same 
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site with a similar author as Haid et al., as described above, and this time the surgeons placed 
either ICBG or local autograft posteriorly around the implant. This change in technique may 
have contributed to a decline in incidence; however, both studies reported that all cases were 
asymptomatic and radiographic incidence of HO was not reported. 
 Both studies by Rihn et al. reported cases of HO; the second study will be considered 
here since it likely includes the patient population in the first study. In 86 patients undergoing 
single-level TLIF with rhBMP-2, the authors found that two patients (2.3%) developed HO.2 
Both cases were symptomatic. It appears the authors did consider asymptomatic cases of HO as 
they included only radiographic outcomes in their definition of a complication, and it appears 
that all patients had CT in follow-up. However, the authors did not report any cases of 
asymptomatic HO.  
 Finally, Crandall et al. retrospectively described a large cohort of 509 patients undergoing 
TLIF at 872 disc levels, all using rhBMP-2. No control group was considered. All patients were 
followed for a minimum of two years. The authors found ectopic bone formation in three patients 
(0.59% of sample or 0.34% of levels treated).16 Again, patients were only evaluated for HO if 
they were symptomatic; asymptomatic patients did not undergo postoperative MRI or CT. This 
study concludes the incidence of symptomatic HO appears very low in a large cohort. 
 The heterogeneity of these studies prevents strong conclusions regarding HO incidence 
rates. Our interpretation is that radiographic HO appears to occur between 0-21% of the time 
with rhBMP-2 use, although better studies are needed. We exclude Haid et al. in this estimation 
on the basis of their technical omission to avoid placing the ACS near the posterior opening. This 
technique appears routinely practiced today, perhaps due to the risk they identified. Symptomatic 
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HO occurs, but the large majority of cases appear to be asymptomatic through at least one year 
of follow-up. 
 The formation of heterotopic bone in TLIF procedures performed with autograft appears 
negligible. Although Haid et al. demonstrated a 13% incidence in 31 patients in their autograft 
control, Mummaneni et al. and Rihn et al. did not report any cases of HO in their samples of 19 
patients and 33 patients, respectively.2,10,15 Additionally, a literature search did not provide any 
evidence of HO in TLIF without rhBMP-2.  
C. Osteolysis  
 In 2006, McClellan et al. published the first reports of osteolytic changes occurring in 
TLIF with rhBMP-2 use. Their retrospective study reviewed 26 patients from their database. At a 
minimum of three months, CT showed bone resorption in 22 of 32 treated levels (69%) on 1mm 
cut imaging.17 Severe osteolysis, defined as defects in greater than 75% of the area of the 
interbody graft or greater than 1 square cm, occurred in seven levels (31%). Additionally, five 
patients with severe osteolysis showed graft subsidence due to loss of endplate integrity. The 
authors note that selection bias occurred in their inclusion criteria as all patients chosen to be in 
the study had CT, which is not routinely indicated postoperatively in their practice. Therefore, 
the study likely selected patients more likely to have complications.  
 Vaidya et al. supported these findings two years later, performing a prospective study that 
also found a high incidence of osteolysis.18 The study included 36 levels fused by TLIF in 26 
patients. Follow-up was relatively lengthy as compared to other studies at a mean 26 months. All 
patients were imaged by radiography, with CT obtained only in a minority of patients, and 
assessments were made by three independent radiologists. In these 36 levels, 29 (81%) met their 
criteria for osteolysis. When these cases presented during follow-up was not specified. Further, 
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in seven patients with endplate osteolysis, the interbody device migrated, provoked symptoms, 
and required revision surgery. The authors attributed this to their technique of placing rhBMP-2 
centrally in the implant, which caused osteolysis directly above and below and allowed 
subsidence. Of note, the authors used PEEK cages for all cases, which may be associated with 
increased rates of osteolysis. This possible relationship will be explored in the next section.  
 Next, Knox, Dai, and Orchowski reported a much lower but sizable incidence in 2011.19 
The study enrolled 77 lumbar levels belonging to 58 patients, all treated with TLIF using 
rhBMP-2. Either PEEK or titanium cages were used. On retrospective review of CT images, they 
found 19 of 77 levels (25%) showed osteolysis at an average of 4.3 months of follow-up. The 
majority of cases with osteolysis (63%) were considered severe, or osteolysis greater than 1 cm. 
Six of these cases showed evidence of graft subsidence and the interbody device migrated in four 
cases, but none required revision.  
 Together, these studies suggest that endplate osteolysis occurs commonly following 
rhBMP-2 exposure in TLIF, but the true rate remains unclear. Incidence varies from 25-81% and 
the studies are limited by selection bias, differences in surgical techniques, and small sample 
sizes. We consider the study of Knox, Dai, and Orchowski to be the most sound of the group due 
to routine use of CT and enrollment of consecutive patients.  
 Three additional studies in the literature also measure osteolytic incidence but consider 
only symptomatic cases. If these studies found evidence of asymptomatic osteolysis during 
follow-up, they were not reported. Since this definition of osteolysis is incompatible with direct 
comparison to the definitions used in the previously reviewed studies, we now consider these 
reports separately. First, Rihn et al., as a part of the same study covered in the previous sections, 
found an incidence of 5.8% in its rhBMP-2 group of 86 patients.2 Patients presented with new 
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onset, worsening low back pain; two of these resolved at one year and the remaining three 
persisted beyond one year. Then, Owens et al. found only a single case in a consecutive cohort of 
204 patients (0.5%).6 The patient became symptomatic from foraminal narrowing, but the 
symptoms eventually resolved without intervention. Finally, in the largest cohort, Crandall et al. 
found a 0% incidence of symptomatic osteolysis in 872 disc levels of open TLIF using rhBMP-
2.16 No cases of cage subsidence nor migration were identified by routine postoperative 
radiographs. Overall, it appears that endplate osteolysis is rarely symptomatic. These studies 
provide important clinical context for the high rates of radiographic osteolysis seen above. 
 As a final note, it appears that the development of endplate osteolysis is not associated 
with autograft use. Similar to HO, both Mummaneni et al. and Rihn et al. did not report any 
cases of osteolysis in their autograft samples of 19 patients and 33 patients, respectively.2,15 
Though these are small samples, the literature does not expand on these sample, and no studies 
have presented any additional evidence of endplate osteolysis in TLIF without rhBMP-2. 
2.3 Review of Confounding Variables  
 
A. Patient Variables   
 
 Studies included in our literature search routinely collected demographic information on 
patient age, sex, and vertebral level(s) undergoing fusion.3-7,14,20 Most of these studies also 
considered BMI, diabetes, and smoking history and status as important confounders. Lubelski et 
al. identified smoking at the time of operation as a statistically significant confounding variable 
that increased the rate of radiculitis (OR 1.76, p=0.03). The same study also recorded baseline 
use of medications including antidepressants, anxiolytics, narcotic analgesics, stimulants, and 
antipsychotics. Wang et al. expanded their definition of comorbidity beyond diabetes alone, 
measuring burden with the Charlson Comorbidity Index.  
 33 
 Additional literature describes other variables which may be of relevance to our study’s 
outcomes. Preoperative steroid injections may alter the risk for developing radiculopathy; some 
studies have described long-term analgesic effects while others have found only a short-term 
benefit for a majority of patients.21,22  Regarding osteolysis, one retrospective review of 88 
patients undergoing TLIF found that osteoporosis, as identified by Hounsfield Units on 
postoperative CT, was a significant risk factor for radiographic complications including cage 
subsidence.23 This finding was supported by a separate retrospective study following over five 
thousand patients.24 Bhattacharjee et al. found an association between chronic preoperative 
opioid use and both non-union and revision surgery.25 Also, Sheinberg et al. found that patients 
in menopause were at greater risk for non-union and revision surgery which the authors 
attributed to bone metabolic imbalances in the menopausal state.26 Finally, some variables may 
be a non-issue; two different studies found that both marijuana use and pre-operative vitamin D 
levels did not affect complication rates or functional outcomes following fusion.27,28  
B. RhBMP-2 Dose   
 
 The literature records a variety of rhBMP-2 doses used in practice, and the exact dose 
providing a reliable fusion without increasing the likelihood of complications remains unclear.   
Although rhBMP-2 associated complications have been felt to be a dose-related 
phenomenon19,29, this has not been proven. Villavicencio and Burneikiene, using a range of doses 
from 1.05-12.0 mg/level, did not identify any significant correlations between dose and 
incidence of radiculitis with logistic regression (p=0.60).4 Khan et al. similarly reported no dose-
related relationship with TLIF-related complications up to 12 mg/level (p=0.91).5 Interestingly, 
another study of 502 multi-level spinal deformity cases found a low incidence of radiculopathy 
(1%) and no correlation with dose using total doses averaging 115 mg (range 40-351).30   
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 Regardless, studies show a trend of surgeons selecting smaller doses over time. Crandall 
et al., after studying a range of doses from 2-12 mg/level, suggest the optimal dose may be 4 
mg/level as this dose was not associated with any postoperative complications and produced a 
98% fusion rate in 65 patients.16 Niu et al. attributed the lower incidence of HO in their study 
than that of previous literature to their dose of 2-3 mg/level.14 Finally, Khan et al. gradually 
reduced their dose from 12 mg/level to 4 mg/level during their 17-year study, aiming to reduce 
complications.5 As these low doses are providing high fusion rates, there is not a compelling 
reason to use more. This logic is consistent with initial FDA safety data that reported no benefit 
beyond a dose threshold in animal models.31   
C. RhBMP-2 Placement   
 
 Surgical technique and rhBMP-2 containment likely play a significant role. Placement of 
the rhBMP-2/ACS complex near neural structures or the foramina may increase the incidence of 
radiculopathy or HO. As mentioned, the high rates HO reported by Haid et al. may have been 
due to placement near the posterior annulus and a lack of posterior packing.10 Further, Singh et 
al. demonstrated a rate of symptomatic ectopic bone formation approximately three times higher 
if rhBMP-2 was mixed with bone graft rather than separately placed anterior to the disc space or 
within the implant.32 In contrast, Crandall et al. reported a low incidence of complications after 
placing the rhBMP-2/ACS complex as far anterior and contralateral as possible within the 
intervertebral space and adding autograft or allograft for posterior backfill.16 With the intent to 
reduce risk of osteolysis, they also did not compress the rhBMP-2/ACS complex, avoiding 
hyperconcentration, and took care not to overdo endplate preparation. Similar techniques were 
employed by Niu et al., who reported relatively low rates of HO.14  
D. Choice of Interbody Device  
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 Polyetheretherketone (PEEK) cages are a popular choice in TLIF due to their 
radiolucency and light material that decreases the rate of subsidence.33 However, a few small 
studies have suggested that PEEK cages may be associated with increased rates of osteolysis and 
decreased rates of fusion in TLIF compared to titanium cages. A retrospective study involving 48 
patients undergoing single-level TLIF with titanium or PEEK implants demonstrated a 60% 
incidence of osteolysis in the PEEK group at 12 months, but this was not seen in the titanium 
group.34 Further, osteolysis was found to be significantly associated with non-union (p=0.007) 
which was disproportionately seen in the PEEK group.  Another retrospective study reviewing 
40 patients found osteolysis in 50% of cases using PEEK versus 10% of cases using metal, and 
PEEK also showed lower rates of fusion.35 However, this study was underpowered to achieve 
statistical significance.  
E. Length of Follow-Up  
 
 Finally, time is an important variable that must be considered. The literature has shown 
varying quantities for radiculopathy and osteolysis depending on when it was measured. First, 
Helgeson et al. described a reduction of osteolysis with time, appearing in 54% of their cohort 
between three to six months and decreasing to 41% between one to two years.36 As a more stark 
example, another study observing 17 cases of PLIF performed with PEEK cages and a high dose 
of rhBMP-2 (12 mg/level) showed a 100% incidence of osteolysis at 3 months but 0% at 6 
months.37 Next, rates of radiculopathy appear to decline with time after it is first detected. Rowan 
et al. showed a high rate (25%) of immediate postoperative radiculopathy strongly associated 
with rhBMP-2 over ICBG (OR=2.33); however, this decreased to 11.6% at a median follow-up 
of 4.1 months.38 Hofstetter et al. explained that the time of onset depends on the underlying 
pathology.39 Radiculopathy due to seroma formation can occur as early as ten days after surgery, 
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while symptoms from inflammatory reactions usually develop between two and four weeks and 
impingement from HO often manifests beyond two months.  
2.4 Review of Relevant Methodology  
A. Study Design  
Prior studies comparing rhBMP-2 with ICBG have designed multi-center, randomized 
controlled trials to successfully measure meaningful differences in outcomes. Burkus et al. 
performed a multicenter randomized controlled trial to compare postoperative outcomes in 
patients receiving either rhBMP-2 or autograft in ALIF.40 They enrolled 131 patients across 18 
clinical sites during a three-year period ending in 2001. Successful randomization was achieved 
using a statistical program that produced sequentially numbered envelopes for each enrollment 
site. Loss to follow-up was 3.8% at twenty-four months postoperative. Statistical significance 
was achieved in comparing intraoperative, radiographic, and functional outcomes.  
 Another successful study using this design was performed by Glassman et al.41 The study 
investigated outcomes over a two-year period in an elderly population undergoing PLF either 
with rhBMP-2 or ICBG. Enrolling 106 participants, the study included cases performed by five 
surgeons. Randomization was performed but the method was not specified. One hundred patients 
(94%) completed the study in accordance with their allocated treatment and provided data 
through 24 months of follow-up. Improvements in resultant fusion grades, complication rates, 
and revision rates in the rhBMP-2 group achieved statistical significance. Together these studies 
demonstrate feasibility for use of the RCT design to compare rhBMP-2 with ICBG.  
B. Randomization 
 An effective means of randomization is illustrated by the influential Spine Patient 
Outcomes Research Trial (SPORT), a large, multi-center study consisting of three concurrent 
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randomized controlled trials. To assure that the number of subjects from each site were 
approximately the same for each group, the study employed a variably blocked randomization 
scheme.42 This means that group allocation was done sequentially within blocks of a 
predetermined size, with the sequence and size of the blocks further varied randomly. This was 
performed by a computer-generated, automated randomization program at the time of 
enrollment. The randomization codes were immediately and permanently embedded in the 
patient’s record, accessible to coordinators and investigators through a secured web site.  
C. Recruitment 
Both Burkus et al. and Glassman et al. as described above recruited participants from the 
population of existing patients at cooperating surgery sites.40,41 Consecutive sampling was used 
in both instances. Of interest, Birkmeyer et al. describe a unique addition in their method of 
recruitment for SPORT. After candidates for participation were identified by research nurses or 
participating surgeons from among their clinic’s patients, videotapes were sent to candidates.42 
The videotapes provided information explaining gaps in current knowledge, risks and benefits of 
various treatments, and information about participation in layman’s terms. The authors state this 
was intended to increase both enrollment and acceptance of randomization by providing 
education about the importance of the research.  
D. Setting 
It is relevant for our study to note the caseload of open TLIF per surgical site in the 
literature in order to determine the number of sites we will need. We report the number of cases, 
number of surgical sites, and time frame of all studies included in our review that were published 
after 2010 in Appendix B. We include this restriction on publication date because of the rapid 
growth in TLIF caseload in recent decades as described in section 1.1 part A.  
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E. Inclusion and Exclusion Criteria  
 Our criteria for participation will be informed by indications and contraindications both 
for TLIF and for rhBMP-2 use. As mentioned, the AANS recommends lumbar fusion, including 
TLIF, for patients with DDD refractory to conservative treatment.43 Further, the FDA statement 
of approval for Infuse™ requires that patients must be skeletally mature, have a diagnosis of 
DDD as confirmed by history and radiology, and experience symptoms refractory to at least six 
months of conservative treatment.  
 Scoliosis and pseudarthrosis or other revision cases can also be indication for TLIF but 
appear to pose relevant differences in their risk for postoperative complications.44 Bridwell et al. 
found an overall complication rate of 36% in their cohort of 81 patients receiving fusion for 
scoliosis; Bradford, Tay, and Hu reported high rates of residual pain, neurologic injury, and 
thromboembolism, commenting that the difficulty in achieving coronal and sagittal balance in 
these cases can limit postoperative success.45,46 Dede et al. reported limited benefit in revision 
cases for patients with DDD, reporting an mean increase of 6.45 points in ODI postoperative 
scores, while 42% of the cohort reported their overall well-being was worse after surgery 
through a follow-up of 24 months. Additionally, the majority of patients undergoing revision 
already have epidural fibrosis at the surgical site which is associated with pain, radiculopathy, 
and an increased risk of damage to the neural structures during the revision.3,47  
The TLIF technique and rhBMP-2 use also have specific contraindications. In their 
review, Mobbs et al. state TLIF should not be performed in patients with extensive epidural 
scarring, arachnoiditis, active infection, or conjoined nerve roots in the operative location or in 
patients with damaged vertebral bodies from trauma or severe osteoporosis.48 Per the 
manufacturer’s instructions, rhBMP-2 use is contraindicated in patients with relevant 
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hypersensitivites or allergies, skeletally immature patients, patients with active malignancy or 
undergoing treatment for malignancy, pregnant patients, or patients with active infection, 
resected tumor, or extant tumor at the operative site.  
In addition, Colom-Beauchamp et al., utilizing a similar design to our study, excluded 
candidates who had undergone any previous attempt at fusion and had prior exposure to any 
bone morphogenetic protein.49 Rihn et al. excluded multi-level cases, cases that included any 
bone graft substitute or extender other than rhBMP-2, and cases for an indication of tumor, 
infection, or trauma.2 Villavicencio and Burneikiene also excluded multi-level cases given the 
rationale that higher per-level doses of rhBMP-2 may be required for multiple level fusions.4 
F. Measurement of Primary Outcomes  
 
 Radiculopathy: The literature widely agreed in their definition of radiculopathy as new 
onset radicular symptoms in a dermatomal distribution following surgery.2-4,6,20 The symptom of 
pain was sometimes measured by the Visual Analog Scale (VAS), including leg pain both 
ipsilateral and contralateral to the surgical side as described by Sebastian et al.7 In most cases, 
however, a method of measurement was not specified and radiculopathy was therefore presumed 
by us to be a clinical diagnosis. Owens et al. included “neurologic deficits” in their definition to 
emphasize symptoms of weakness, numbness, and tingling but did not mention that an additional 
measurement tool was used.6 Finally, Villavicencio and Burneikiene clarified that the clinical 
development of radicular symptoms must be between a few days to several weeks 
postoperatively after an initial period of improvement.4  
 As mentioned, there was variability in inclusion or exclusion of compressive etiologies in 
the definition which influenced the role of imaging. Wang et al. specifically quantified 
radiculitis, looking for and excluding compressive etiologies using MRI and CT on all patients 
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with radicular symptoms.20 Khan et al. and Rihn et al., on the other hand, did report compressive 
etiologies and reviewed only CT images for all patients.2,5 Other compressive causes not 
requiring imaging were determined using clinical judgement or laboratory tests. Owens et al. 
defined seroma as a clinically evident fluid collection with either a negative culture or showing 
resolution without the use of antibiotics.6 This definition distinguished seroma from infection, a 
separate complication.   
 HO: Assessment of HO was made exclusively by appearance on CT. All studies designed 
to assess radiographic HO obtained CT at six months for all patients.2,10,13,14  Niu et al. presented 
a grading system to classify ossification as adapted from Joseph and Rampersaund.13,14 The scale 
operates on a grade between 0-3, and HO is defined as grade 3A, 3B, or 3C. Of note, grade 1 or 2 
are suggestive of desirable fusion. This grading system is reproduced in Table 2.  
 Osteolysis: Knox et al. presented in detail their method of measuring osteolysis, a 
technique that has been emulated in subsequent works. The authors included in their 
retrospective study patients with CT scans at two time intervals—the first within two weeks 
postoperatively and the other between two and nine months, with most obtained at the six month 
follow-up visit. All CT scans were performed with 2.5 mm cuts and included sagittal and coronal 
reconstruction. Then, a reviewer compared the two images for signs of osteolysis, defined as 
bone resorption 1 mm or greater. Cases were then classified as mild (1-5mm), moderate (5-
9mm), or severe (>1cm). Also, Saigal et al. observe that it can be difficult to differentiate 
rhBMP-2-related osteolysis from infection on imaging alone.50 They recommend that infection 
be excluded based on the patient’s clinical condition and if necessary laboratory tests such as 
ESR, CRP, and blood cultures.  
G. Blinding  
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 Due to the nature of the intervention, surgeons are not able to be blinded to the treatment 
group. However, the literature demonstrates ways to blind assessment of outcomes. The studies 
we have reviewed that consider a control group have consistently blinded evaluation of 
radiographic outcomes.2,7,41 As an example, Khan et al. used two blinded orthopedic surgeons to 
separately evaluate all imaging, and a third independent observer resolved any discrepancies.5  
 Another study demonstrated that it may be possible to effectively blind the participants in 
our study to their group allocation. This study enrolled 92 patients undergoing posterior LIF with 
ICBG and blinded them to which of their iliac crests would be providing the graft.51 Donor sites 
were randomized 1:1 between the left and right iliac crest and harvest was performed through the 
primary incision for the fusion. At six weeks, three months, six months, and one year, only 22 
patients (24%) were consistently correct in identifying the harvest site. Additionally, VAS pain 
scores did not differ between the affected and unaffected iliac crests at all time points.  
H. Sample Size Calculation  
 
Since each of our three primary outcomes will be assessed for statistical significance 
individually, our sample size for each was considered separately. Each calculation was 
performed using, in our judgement, the best incidence rates from our literature review. 
Radiculopathy: To calculate our sample for radiculopathy, we used the incidence rates as 
published by Kahn et al. This work was selected because it reflects our study well by considering 
only patients undergoing TLIF for DDD, it quantifies radiculopathy rather than radiculitis alone, 
and it quantified the incidence in an ICBG control group as a part of the same study. 
Additionally, the authors found the lowest incidence rate among the studies that reported a 
difference and would therefore overestimate the sample size if the larger rates reported by the 
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other studies are in fact closer to the true value. The reported incidence in this study was 10.8% 
for the interventional group and 1.9% for the control.  
HO: We selected the rates reported by Niu et al. for our calculation of HO. The study has 
the largest cohort, by far, of the studies considered, had superior methodology by routine use of 
CT, and considered a control group as a part of the same study. Similarly, this study also reports 
the lowest incidence among the studies that found a difference. This work found an incidence of 
13.5% for the rhBMP-2 group and 1.6% in the autograft control.  
Osteolysis: Finally, the work of Rihn et al. appears to provide the best estimate for 
incidence of osteolysis. First, the rates report the incidence of symptomatic cases, which bodes 
well for clinical significance. Next, the study compares incidence against an ICBG control. The 
sample size is smaller than some of the other studies but larger than all the studies considering 
radiographic cases alone. The incidence is also much lower than the other studies including 
radiographic appearance in their definition. Thus, this work will provide a large enough sample 
to consider both radiographic and symptomatic cases. The incidence published by this study is 
5.8% for the intervention and 0% in the control. 
2.5 Conclusion 
 
 While rhBMP-2 associated complications following TLIF have been described in the 
literature for over a decade, uncertainty continues to limit providers’ ability to fully inform 
patients. All existing studies are observational in design, and many involve small sample sizes. 
Most have a single-center focus, limiting generalizability to different practices. Heterogeneity 
exists in outcome definitions, execution, and reporting of adverse events. These limitations may 
explain, at least in part, the range of conclusions that are reported. Additionally, scientific flaws 
inherent to cohort studies such as a propensity toward selection bias resulting in baseline 
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differences between groups prevent definitive conclusions regarding the complication rate of 
rhBMP-2 from this data. This highlights the need for a prospective, multi-center, experimental 
study of sufficient sample size to characterize complication incidence. In our review of the 
literature, we have surveyed previous reports of our primary outcomes, identified confounding 
variables, and described methodology that will inform our study design. Our proposed study will 
add to the literature by using a high-quality study design to increase our understanding of this 
product that thousands of patients are already receiving.  
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CHAPTER 3: METHODS 
 
3.1 Study Setting and Design 
 
 We propose a randomized, single-blinded, two-armed, controlled trial to determine the 
relative risk of developing three postoperative complications in patients who receive rhBMP-2 
versus ICBG for TLIF. This study will include ten sites across the United States. The rationale 
for our number of included sites is provided in Appendix B along with a list of sites intended to 
be approached for participation. The study will be performed over a span of two years. 
Participants will be recruited on a rolling basis given that their surgery will occur by the end of 
month 17 of the study. After enrollment, participants will be randomly assigned to either the 
intervention or control group in a 1:1 ratio without stratification. Surgeons will be informed of 
the allocation before surgery is performed. Postoperatively, patients will be assessed for primary 
and secondary outcomes during follow-up visits at three weeks, three months, and six months. A 
timeline is shown in Table 1.  
Table 1: Proposed Timeline 
3.2 Study Population, Sampling, and Recruitment  
 
 The target population of our study will be all U.S. adults between the ages of 21-75 with 
a diagnosis of lumbar DDD and symptoms refractory to an adequate trial of conservative 
management. Our study population will be all persons within the target population that are 
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patients actively seen at our participating medical centers within the study timeframe. Our 
sample will be recruited from our study population by means of consecutive sampling. 
 Inclusion and exclusion criteria will be in accordance with guidelines and/or precedents 
for both TLIF surgery and rhBMP-2 use as detailed in our review in section 2.4 part C. For 
logistical reasons, patients must also report their intention to attend follow-up with the same 
medical team that performed the surgery for at least six months postoperatively. We also include 
that patients must have previously elected to undergo LIF with consent for a posterior approach. 
This was decided for ethical reasons as we want to avoid undue influence on patient choice of 
one approach over another. Patients who do not agree to undergo randomization will be excluded 
from the study. A full list of inclusion and exclusion criteria is included in Figure 1.  
Figure 1: Inclusion and Exclusion Criteria 
Candidates will be identified as eligible by their surgeons, other health care workers 
involved with the patient’s care, or research nurses at each site. Candidates will be approached 
by a research nurse for an explanation of the trial either in person, through video chat, or by 
phone. Candidates will then receive a link to a video further explaining the study’s rationale, 
design, and risks and benefits, with an invitation to participate. At this time, candidates may give 
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their consent, but they will also be encouraged to discuss enrollment with their surgeon or an 
advanced practice provider associated with the medical group either in person or via telehealth if 
they wish. New candidates will continue to be approached until sufficient enrollment is reached.  
3.3 Participant Protection and Confidentiality  
 
 We will attain Institutional Review Board (IRB) approval for our study at each enlisted 
site prior to recruitment according to the 100 IRB Protocol for review of human subject research 
protocols or FDA-regulated activities involving human participants. In accordance with IRB 
requirements, candidates will receive our version of the Authorization and Consent for 
Participation in Research Project form which includes a description of the research project, risks 
and benefits, efforts to ensure confidentiality, and a statement of voluntary participation and 
withdrawal. A sample consent form is included in Appendix A. Medical interpretive services 
will be utilized for any patient whose primary language differs from that of the researcher 
providing this information. All candidates must provide written, informed consent prior to 
enrollment. 
 To protect patient confidentiality, all personnel involved in the study will complete a 
Health Portability and Accountability Act (HIPAA) training session and will submit the 
certification to their corresponding IRB. Participant data will be kept confidential within 
password-protected encrypted servers and according to HIPAA guidelines. Each participant’s 
file will be de-identified and codified prior to data analysis. De-identified information may be 
kept at the conclusion of the study if participants are separately consented to participate in any 
additional studies that are designed to elaborate on the present one. If participants are not 
enrolled in any further studies at the conclusion of this study, all data will be destroyed.  
3.4 Study Variables and Measures 
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A. Baseline Assessment   
 
 Enrolled participants will be assessed for demographic characteristics, comorbidity, and 
baseline functional status before randomization. We will record age, sex, type of DDD diagnosis, 
vertebral level(s) requiring operation, BMI, presence of diabetes or menopause, comorbidities 
per the Charlson Comorbidity Index (CCI), smoking status and history, medications with 
emphasis on antidepressants, anxiolytics, narcotic analgesics, and oral or injectable 
corticosteroids, ODI score, VAS leg pain score, VAS back pain score, and Short-Form 36 score. 
The presence of osteoporosis will be assessed by Hounsfield Unit measurements on the first set 
of CT images collected for all patients within two weeks after surgery as described by Lee et al.1 
B. Intervention 
 
 The experimental group will undergo TLIF procedure utilizing rhBMP-2 (brand 
Infuse™) at a dose of 4.2mg/level. Surgeons will be instructed to place the rhBMP-2/ACS 
complex as anterolateral as possible, with care to avoid placement close to the posterior annulus, 
and to avoid over-compression of the ACS. The procedure will be performed using any titanium 
cage of the surgeon’s choice, and local autograft or allograft can be used for backfill at the 
surgeon’s discretion. Each surgery will be performed in conjunction with pedicle screw 
instrumentation and posterolateral fusion.  
C. Control 
 Our control arm will receive TLIF in conjunction with ICBG. The autograft will be 
harvested through the primary surgical incision to avoid cutaneous damage that would 
compromise patient blinding. Titanium cages will be used for all cases. The primary graft may 
be combined with local autograft or allograft at the surgeon’s discretion. Pedicle screw 
instrumentation and posterolateral fusion will also be performed with each procedure.  
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D. Measurement of Primary Outcomes  
 Radiculopathy will be defined as new onset radicular symptoms in a dermatomal 
distribution following surgery. We include compressive etiologies resulting from hematoma, 
seroma, scar tissue, or heterotopic bone and non-compressive radiculitis in our definition. We 
will exclude symptoms from iatrogenic injury and incomplete decompression. Back and leg pain 
will be assessed preoperatively, perioperatively, and at each follow-up visit with VAS ratings as 
shown in Appendix C. Other neurologic symptoms such as weakness, numbness, and tingling 
will be described clinically. As radiculopathy is a diagnosis of exclusion, any laboratory tests or 
earlier imaging needed to rule out other potential etiologies will be used appropriately based on 
clinical suspicion.  
 Both HO and osteolysis will be evaluated by high-resolution axial CT with sagittal and 
coronal reconstruction. Images will be obtained within two weeks after surgery and again at six 
months. We define HO as any new bone growth that extends outside of the annulus and 
encroaches on the spinal canal or vertebral foramen. We adopt the grading system presented by 
Niu et al., reproduced in Table 2, where HO is defined as ossification of grade 3A, 3B, or 3C.2  
Table 2: Heterotopic Ossification Classification 
Osteolysis will be defined as new bone resorption of greater than 1 mm at six months. We will 
use the same grading system as Knox et al., classifying cases as  mild (1-5mm), moderate (5-
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9mm) or severe (>1cm).3 Radiographic interpretation will be performed by two independent 
orthopedic surgeons for all images. Any discrepancies will be resolved by a third orthopedic 
surgeon. Review will occur at the time the images are obtained so that any radiographic 
ambiguities, such as infection, can be clarified with clinical assessment or laboratory testing.  
E. List of Secondary Outcomes  
 
 Data will be collected on all patients for intraoperative, perioperative, and postoperative 
outcomes. Intraoperative and perioperative variables will be assessed up until the patient leaves 
the hospital, but postoperative outcomes will be assessed during follow-up. The intraoperative 
outcomes of operative time, estimated blood loss, volume of transfusion required, neurologic 
injury, and vascular injury will be recorded. Perioperative outcomes include length of hospital 
stay, minor adverse events, and severe adverse events. Minor adverse events will consist of any 
of the following: wound complications, abscess formation, acute kidney injury, deep vein 
thrombosis, pneumonia, urinary tract infection, anemia requiring transfusion, and ileus. Cardiac 
arrest, stroke, sepsis, myocardial infarction, renal failure, pulmonary embolism, ventilator use, 
unplanned intubation, return to operating room, and death will be considered severe adverse 
events. Finally, postoperative outcomes will be divided into secondary postoperative 
complications and indicators of surgical success. These secondary postoperative complications 
include iliac crest pain, iliac crest infection, interbody cage subsidence, interbody cage 
migration, change in spinal curvature or height, revision surgery, and development of new 
malignancy. Indicators of surgical success are postoperative ODI score, VAS score for back 
pain, VAS score for leg pain, Short-Form 36 score, fusion at six months, and reoperation rate.  
 Although we recognize surgical success is routinely assessed beyond six months, we 
include these postoperative outcomes to allow our cohort to easily transition to any additional 
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studies that may wish to follow our participants beyond our proposed time frame. It is possible 
our study, which will require substantial effort and resources, would be attractive to further 
analysis of outcomes relevant to the rhBMP-2 debate such as overall fusion rate and long-term 
incidence of malignancy.  
3.5 Methodology 
A. Assignment of Intervention 
 
 Computer-generated randomization will assign patients in a 1:1 ratio to either the 
intervention or control group using a variably blocked randomization scheme. The allocation will 
occur at the time of enrollment and will immediately be imbedded in the patient’s medical 
record. Surgeons will view the allocation before operating but the patient will remain blinded.  
B. Blinding 
 Due to the nature of the intervention, each surgeon and their operating team will not be 
blinded to their participants’ group allocations. The same providers are encouraged to follow the 
patient postoperatively, so all clinical assessments will also not be blinded. However, all 
radiographic interpretations will be made by blinded orthopedic surgeons. Patients will remain 
blinded to their group allocation throughout their participation in the study.  
C. Data Collection 
 Baseline assessment will be conducted by a combination of patient interview, patient 
self-administered survey, and physician survey. Intraoperative outcomes will be collected during 
routine postoperative documentation by the surgical team. Perioperative outcomes will be 
recorded either by the surgical team or by research nurses that will follow patients during their 
hospital course. Research nurses will ensure an assessment is entered for each outcome and 
provide continuity if patients are transferred to a medical service during their stay. Radiculopathy 
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and secondary postoperative outcomes will also be assessed by patient interview, patient self-
administered survey, and physician survey each follow-up visit. The clinical primary outcome, 
radiculopathy, must be collected and entered to the study’s data system by the surgeon or an 
associated medical doctor or advanced practice provider. Secondary outcomes may be collected 
by any health care provider with the surgical team or a research nurse. The other primary 
outcomes will be assessed by imaging. High-resolution CT will be obtained within two weeks of 
surgery and at six months postoperatively. Interpretation will be made within one week after 
imaging is obtained by the independent assessors who will then directly enter their findings into 
the study’s data system.  
3.6 Statistical Analysis  
 
 Data analysis will be conducted during the final month of the study according to the 
intention-to-treat principle. If the cross-over rate between the intervention and control groups is 
greater than 3%, per-protocol analysis will also be performed; however, we do not anticipate that 
this should occur as participants must agree to be blinded to their group to enroll in the study. 
The incidence proportion of each primary outcome will be statistically analyzed using Fisher’s 
exact test. Further, osteolysis will be analyzed for statistical differences in severity between our 
intervention and control groups using the Wilcoxon Rank Sum test. Other baseline information 
and secondary outcomes will be analyzed with an unpaired t-test for continuous variables and 
Fisher’s exact test for categorical variables. If differences are found in baseline characteristics 
between the intervention and control groups, single or multiple logistic regression will be 
performed for the primary outcomes and secondary categorical outcomes, and single or multiple 
linear regression will be performed for secondary continuous outcomes. Measurements of 
function, including ODI, VAS, and SF-36 scores, will be compared pre and postoperatively 
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within each allocation group using paired t-tests. Then, the mean difference of pre and 
postoperative scores will be compared between groups using an unpaired t-test. A p value < 0.05 
will indicate a significant result for all tests. Finally, if our study is performed with industry 
sponsorship, we will share our raw data with independent reviewers for statistical analysis to 
limit industry influence.  
3.7 Sample Size Calculation 
 
 The sample size was calculated using what we consider the best incidence proportion 
published in the literature for each of our three primary outcomes as previously described in 
section 2.4 part G. The calculation was made with G*Power 2 software, and each calculation 
accounted for an alpha of 0.05, power of 80%, and a 1:1 allocation between the intervention and 
control groups. Two-sided tests were used for calculations of radiculopathy and HO since the 
literature reports these complications can exist with the use of our control, ICBG. Although we 
concluded that the risk of HO with autograft appears to be negligible, since two studies reported 
a very low incidence we employed a two-sided test so that we may err on the side of an over-
estimation rather than undermine our study with an insufficient sample. However, since our 
literature review did not reveal any cases of endplate osteolysis following autograft, we 
employed a one-sided test for our third calculation. We also, we believe, overestimated the 
incidence proportion of osteolysis in our control for this calculation in order to use a non-zero 
value; our literature review found an incidence of 0%, but we used 0.5%. This value would only 
overestimate our final sample calculation. The calculation for each complication is shown in 
Appendix D.  
 The sample size for radiculopathy, heterotopic ossification, and osteolysis was calculated 
to be 256, 164, and 302, respectively. We will use the largest calculation, 302, as our sample size 
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for the entire study so that we may achieve statistical significance for each outcome. We note the 
benefit that this sample size will increase the power in the analysis of the other two primary 
outcomes. Finally, we will account for a 15% drop out/loss to follow up rate for a final sample 
size of 356. We will allocate 178 participants in each treatment arm.  
3.8 Resources  
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2. Niu S, Anastasio AT, Faraj RR, Rhee JM. Evaluation of Heterotopic Ossification After 
Using Recombinant Human Bone Morphogenetic Protein-2 in Transforaminal Lumbar 
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CHAPTER 4: CONCLUSION 
 
4.1 Study Advantages and Limitations 
 
 Our study’s biggest advantage is its experimental design. The RCT format minimizes 
selection bias and known and unknown confounding variables to a degree not previously seen in 
the literature. We are also the first study of those measuring our primary outcomes to blind 
patients to their intervention which will reduce respondent and recall bias. Our use of an equally 
sized control group will allow direct comparison between our intervention and the gold standard 
treatment. Finally, while most other studies have retrospectively reviewed available patient 
records, our prospective model has been designed to enroll a sufficient sample size to achieve 
statistical significance.  
 Additional advantages exist as a result of our design and methodology. Our routine use of 
high-resolution CT will provide superior detection of HO and osteolysis compared to radiograph.  
By limiting our fusion approach to TLIF, we will help characterize the complications of this 
technique independent from PLIF. Finally, our use of multiple sites and surgeons across the 
United States will increase the generalizability of our results to a broad population.  
 Despite these strengths, we recognize our study will have several limitations. First, our 
lack of blinding of clinical assessments leaves the possibility for observation bias. Next, some of 
the studies in our literature review have suggested a lower incidence of our primary outcomes 
than the figures used in our sample size calculation, and our study will not be powered to detect 
differences this small. Our inclusion of both compressive and non-compressive causes in our 
definition of radiculopathy may complicate clinical application of our results as these two 
etiologies may produce different courses of symptoms. Also, our six months of follow-up may 
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not be long enough to describe the course of some symptoms that may resolve spontaneously, 
and it will not report long-term values of fusion rates nor reductions in disability.  
 There are also limitations of generalizability. Our study will not be generalizable to 
minimally-invasive TLIF which is rapidly increasing in use and may broadly become the 
technique of choice in the coming decades. Likewise, our results will not be generalizable to the 
minority of TLIF cases that are performed for non-degenerative diagnoses.  
 Finally, we recognize our study is intensive and will require a significant amount of 
personnel, coordination, and resources. The necessary financial investment will likely require the 
support of industry, providing a potential source of bias.  
4.2 Clinical Significance 
 
 Hundreds of thousands of patients have turned to TLIF to alleviate their symptoms from 
lumbar DDD.1 Hundreds of thousands more are likely to undergo TLIF in the coming decades, 
with the number of cases boosted by the aging population, higher expectations of functioning, 
and the continued advancement of surgical techniques. Future procedures have the potential to be 
performed with rhBMP-2, a product that can help patients avoid the comorbidity of ICBG and 
may improve their chances of a successful surgery.2,3 These meaningful advantages explain why 
rhBMP-2 is currently used in about half of TLIF surgeries despite remaining as an off-label use.4 
 Unfortunately, the drive to use rhBMP-2 in TLIF has outpaced our knowledge of its 
safety. The literature has described cases of radiculopathy, heterotopic ossification, and vertebral 
osteolysis after this use of rhBMP-2 which can cause patients further back pain, leg pain, and 
radicular symptoms or even destabilize hardware and require reoperation.5,6 Yet, the risk of these 
complications has not been studied well, and patients and surgeons must weigh the risks and 
benefits of rhBMP-2 with incomplete information.  
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 Simply put, patients deserve to have high-quality studies that examine the product in the 
way it is being used. Our study will meet this need by performing a randomized controlled trial, 
the premier study design of scientific research, and will enroll patients from across the United 
States for this purpose. Since rhBMP-2 is already used so widely, our findings will be of great 
relevance regardless of the direction of our final conclusions. If our findings support the claim 
that postoperative complications appear more common with rhBMP-2 use, patients will benefit 
as they may avoid these complications by choosing alternative options. If rhBMP-2 appears safe, 
patients will also benefit as they may be reliably encouraged to enjoy the advantages of its use. 
Finally, if our study finds no difference in postoperative complication incidence, our findings 
could help support FDA approval for rhBMP-2 in TLIF. This formal approval would reduce 
financial and logistical barriers to rhBMP-2 use and increase accessibility for patients who may 
benefit.  
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APPENDIX A: Consent and Privacy Rule Authorization Form 
CONSENT FOR PARTICIPATION IN A HUMAN RESEARCH PROJECT 
Study Title: Complications of Recombinant Human Bone Morphogenetic Protein-2 Use in Open 
Transforaminal Lumbar Interbody Fusion  
Principal Investigator: Arya Varthi, MD  
Invitation to Participate and Description of Project  
You are invited to participate in a research study designed to quantify adverse events that may 
occur with use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in 
transforaminal lumbar interbody fusion (TLIF). You have been asked to participate in this study 
because your provider identified you as being an adult age 21-75 with a diagnosis of 
degenerative disc disease that has not improved with conservative management, and you have 
decided to undergo surgical treatment using lumbar interbody fusion. RhBMP-2 is a product that 
causes bone formation and can be useful in fusion surgery. There will be approximately 356 
participants in this study across ten clinical sites in the United States. 
To decide whether or not you wish to be a part of this research study you should know enough 
about its risks and benefits to make an informed decision. This consent form gives you detailed 
information about the research study, which a member of the research team will discuss with 
you. This discussion should go over all aspects of this research: its purpose, the procedures that 
will be performed, any risks of the procedures, possible benefits and possible alternative 
treatments. Once you understand the study, you will be asked if you wish to participate; if so, 
you will be asked to sign this form.  
Description of Procedures  
If you decide to participate in this study, you will be asked questions about your demographic 
information and medical history before you have surgery. Information will be collected about 
your age, gender, spinal diagnosis, medications, and other medical conditions you may have. 
You will also complete a few surveys on your own that will help us learn about the symptoms 
you experience and how it impacts your life. These surveys are often completed by patients 
before undergoing spine surgery, even if they are not a part of a research study. The surveys you 
will complete are the Visual Analog Scale, Oswestry Disability Index, and Short-Form 36 score.  
After this information is collected, a computer program will randomly assign you to either Group 
A or Group B. The group you are assigned to will be made known to your surgeon, but you will 
not be told which group you are in until after the study is completed. We temporarily withhold 
this information from you because it helps increase confidence that our results are accurate. If 
you are in Group A, your surgeon will use rhBMP-2 during your TLIF procedure. If you are in 
Group B, your surgeon will not use rhBMP-2. Instead, your surgeon will take material from your 
hip bone (also called your iliac crest) to be used in your TLIF procedure. If material is required 
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to be taken from your iliac crest, this will be performed in the first few minutes after you are put 
under anesthesia for your surgery.  
The study will also collect information about how you do in the hospital after your surgery and 
before you go home. If you have any surgical or medical complications, this will be recorded.  
After you leave the hospital, you will attend follow-up appointments with your surgeon or other 
medical doctors or advanced practice providers associated with your surgeon. You will be asked 
to attend appointments three weeks, three months, and six months after your surgery. These 
follow-up appointments are mainly routine visits where your provider will be able to assess your 
progress and monitor for complications. Your provider will ask you about any symptoms you 
may be experiencing. You will also be asked to fill out the same surveys that you did at the 
beginning of the study (VAS, ODI, SF-36). The surveys should only take a few minutes.  
Finally, you will also be asked to obtain radiographic images of your lower spine using high-
resolution computed tomography (CT) scans. Sometimes they are also called CAT scans. You 
will be asked to obtain these scans within two weeks following your surgery, and then again 
around six months. These images will be reviewed by your doctor in order to treat you. 
However, the images will also be shared with independent surgeons who will assess them to see 
if you have developed any complications. These surgeons will not able to identify you and will 
not be given any of your personal or medical information.  
In this study we are evaluating if adults who receive rhBMP-2 with TLIF experience different 
amounts complications after surgery than patients who use bone harvested from their iliac crest.  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This website will not include information that can identify you. At most, the 
website will include a summary of the results. You can search this website at any time.  
Risks and Inconveniences  
You should know that using rhBMP-2 is not approved by the United States Food and Drug 
Administration (FDA) for use in TLIF. Using rhBMP-2 in this manner is considered an off-label 
use. Adverse events that have been reported with rhBMP-2 include the following: back pain, leg 
pain, inflammation, bone formation outside of the intended space, fluid collections, weakening of 
the vertebral surfaces, development of antibodies, cancer, implant loosening or movement, non-
union, retrograde ejaculation, allergic reaction, anaphylactic reaction, bone fracture, bowel or 
bladder problems, change in mental status, damage to internal organs, dural tears, gastrointestinal 
complications, incisional complications, infection, itching, localized edema, and scar formation.  
Alternatively, taking bone from the iliac crest to use in your surgery is considered the standard 
treatment. Known risks associated with iliac crest graft include: nerve damage, blood vessel 
damage, infection, pelvic fractures, pain, bleeding, hematoma, sensory loss, and defect hernias.  
Participation in this study may involve risks that are currently not known.  
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Benefits  
If you receive rhBMP-2 as a part of your surgery, you may experience a benefit from not having 
to give a part of your iliac crest to be used in the surgery. You may also have a slightly increased 
chance of having a solid fusion. If you participate in this study in either group, you will help 
future patients understand if rhBMP-2 is associated with more risks or if it is as safe as standard 
treatment.   
Economic Considerations  
There is no direct compensation associated with this study. There are no costs associated to 
participate as the intervention will be given free of charge should you be randomized to receive 
it. You will be still responsible for any deductibles or copays required by your insurance 
company for your TLIF surgery. If you have any questions regarding your insurance coverage, 
please contact your insurance company directly. There will be no financial penalty for 
withdrawing for the study.  
Confidentiality  
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State Law. 
When the results of the research are published or discussed in conferences, no information will 
be included that would reveal your identity unless your specific consent for this activity is 
obtained.  
Information about your study participation will be entered under a unique identification number 
in a password-protected software and stored on secure servers until needed for statistical 
analysis. Health Insurance Portability and Accountability Act (HIPAA) standards will be met 
and maintained for all devices and personnel. Only approved research personnel will have access 
to your medical records in order to verify information required for the study. Any information 
that is not relevant will not be extracted from your medical records. Data auditing will be 
performed at random points throughout the trial to ensure no inappropriate viewing or disclosure 
of protected health information has occurred All records no longer needed for research purposes 
will be destroyed in accordance with HIPAA requirements. All data and records used in the 
study will be destroyed after data analysis has concluded, unless you have given your specific 
consent to share your data with separate research study. Representatives from committees at each 
participating site that review, approve, and monitor research on human subjects may inspect 
study records during internal auditing procedures. However, these individuals are required to 
keep all information confidential.  
Voluntary Participation and Withdrawal  
Participating in this study is voluntary. You are free to choose not to take part in this study. 
Refusing to participate will involve no penalty or loss of benefits to which you are otherwise 
entitled (such as your health care outside the study, the payment for your health care, and your 
health care benefits). You will not be able to enroll in this study if you do not consent to be 
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randomized to either Group A or Group B. You must also acknowledge that you will not be 
informed of which group you are placed in until after your six month follow-up visit.  
If you do become a participant, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you can call a member of the research team at any 
time and tell them that you no longer want to take part. Withdrawing from the study will involve 
no penalty or loss of benefits to which you are otherwise entitled. It will not harm your 
relationship with your providers or the hospital at which they are employed.  
When you withdraw from the study, no new health information identifying you will be gathered. 
Information that has already been gathered may still be used and given to others until the end of 
the research study, as necessary to ensure the integrity of the study and/or study oversight.  
Questions  
We have used some technical terms in this form. Please ask about anything you don't understand 
and consider this research and the consent form carefully, as long as you feel is necessary, before 
you decide to participate.  
Authorization  
I have read (or someone has read to me) this form and have decided to participate in the project 
described above. Its general purposes, the particulars of my involvement and possible hazards 
and inconveniences have been explained to my satisfaction. My signature also indicates that I 
have received a copy of this consent form.  




Signature of Principal Investigator: ____________________________________ 
Or Signature of Person Obtaining Consent: ______________________________ 
Date: ____________________________________________________________  
If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator Arya Varthi, MD.  
If, after you have signed this form you have any questions about your privacy rights, please 
contact your site’s Privacy Officer at XXX-XXX-XXXX. If you would like to talk with someone 
other than the researchers to discuss problems, concerns, and questions you may have concerning 
this research, or to discuss your rights as a research subject, you may contact your site’s Human 




APPENDIX B: Estimation of Number of Participating Sites 
 
 
This table includes information from all studies included in our literature review that performed 
exclusively TLIF and were published after 2010. The rate of cases per site per month was 
calculated in order to estimate how many participating sites we will need to enroll for our study.  
 




Crandall et al.  rhBMP-2 only 509 1 96 5.3 
Khan et al.  both 191 1 216 0.88 
Lubelski et al.  rhBMP-2 only 216 1 107 2.0 
Owens et al.  rhBMP-2 only 204 1 48 4.3 
Sebastian et al.  both 77 1 52 1.5 
Villavicencio and 
Burneikiene 
rhBMP-2 only 204 unclear 31 NA 
Wang et al. both  223 1 78 2.9 
Niu et al.  rhBMP-2 only  927 1 126 7.4 
Knox et al.  rhBMP-2 only 58 1 67 0.87 
  
Average= 3.1/month = 49.6 per site for length of study = 7.2 sites = 8 sites  
We add 2 additional sites for margin = 10 sites 
 
This estimate may be an overestimate of the true value of sites we need for our study. Each site 
may have performed more TLIFs than were included in their studies. We do know that several 
studies excluded several cases due to insufficient follow up or not having the preferred method 
of imaging available. Further, studies that reported only cases which used rhBMP-2 may or may 
not have performed many other TLIFs at that site that did not use rhBMP-2. Finally, the present-
day amount of cases are likely much higher than those reported by these studies since the amount 
of fusion surgeries has doubled in recent decades. These studies describe the caseload between 
1997-2008.  
 
Conversely, this estimate may be an underestimate of the true value needed. This estimate 
calculates the number of cases that may be performed at an average clinical site, but it is not 
known how many of these patients would be willing to be enrolled in a blinded RCT.  
 
Sites to be approached for participation: Yale University School of Medicine, New Haven, CT; 
Northwestern University Feinberg School of Medicine, Chicago, IL; Washington University in 
St. Louis, St. Louis, MO; Cleveland Clinic Lerner College of Medicine, Cleveland, OH; 
University of Louisville School of Medicine, Louisville, KY; Emory University School of 
Medicine, Atlanta, GA; Sonoran Spine Center, Phoenix, AZ; NYU Langone Orthopedic 
Hospital, New York, NY; Wake Forest School of Medicine, Winston-Salem, NC; Walter Reed 
Army Medical Center, Washington, DC.  
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APPENDIX C: Visual Analog Scale for Back and Leg Pain  
 
Name: _______________________________  
Date of Birth: ______ / ______ / ______  
Date:_____/_____/_____  
 
Visual Analog Scale: Back and Leg Pain 
1. Please mark on the line below how much pain you have had from your back, on average, 
over the past week:  
 
2. Please mark on the line below how much pain you have had in your worst leg, on 





3. If you have pain in the other leg, please mark on the line below how much pain you have 











APPENDIX D: SAMPLE SIZE CALCULATION  
 
The following calculations were made using G*Power 2 software.  
 
Alpha (level of significance) = 0.05 
Beta (type II error) = 0.20 
Group allocation ratio= 1:1  
 
This study is powered at 80% for our hypothesis regarding osteolysis, meaning that 80% of 
studies would be expected to produce a statistically significant result for the given effect size. 
Our study’s power is greater than 80% for our hypotheses regarding radiculopathy and 
































By using the largest calculated sample size, 302, and accounting for a 15% loss to follow-
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